KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $89.2 million.

  • Travere Therapeutics' Shares Outstanding (Weighted Average) rose 1472.25% to $89.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.2 million, marking a year-over-year increase of 1472.25%. This contributed to the annual value of $78.9 million for FY2024, which is 622.27% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Shares Outstanding (Weighted Average) is $89.2 million, which was up 1472.25% from $88.9 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Shares Outstanding (Weighted Average) registered a high of $89.2 million during Q3 2025, and its lowest value of $56.3 million during Q1 2021.
  • In the last 5 years, Travere Therapeutics' Shares Outstanding (Weighted Average) had a median value of $74.3 million in 2023 and averaged $71.8 million.
  • Per our database at Business Quant, Travere Therapeutics' Shares Outstanding (Weighted Average) surged by 3531.29% in 2021 and then skyrocketed by 193.14% in 2024.
  • Travere Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $59.8 million in 2021, then increased by 6.56% to $63.8 million in 2022, then rose by 16.48% to $74.3 million in 2023, then rose by 6.22% to $78.9 million in 2024, then grew by 13.11% to $89.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $89.2 million for Q3 2025, versus $88.9 million for Q2 2025 and $88.4 million for Q1 2025.